{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T23:14:25Z","timestamp":1785539665080,"version":"3.56.0"},"reference-count":60,"publisher":"MDPI AG","issue":"7","license":[{"start":{"date-parts":[[2023,6,22]],"date-time":"2023-06-22T00:00:00Z","timestamp":1687392000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004587","name":"Ministerio de Ciencia e Innovaci\u00f3n of Spain","doi-asserted-by":"publisher","award":["CP19\/00104"],"award-info":[{"award-number":["CP19\/00104"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Instituto de Investigaci\u00f3n Carlos III","award":["CP19\/00104"],"award-info":[{"award-number":["CP19\/00104"]}]},{"name":"European Social Fund","award":["CP19\/00104"],"award-info":[{"award-number":["CP19\/00104"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Antibiotics"],"abstract":"<jats:p>Phage therapy is an alternative therapy that is being used as the last resource against infections caused by multidrug-resistant bacteria after the failure of standard treatments. Pseudomonas aeruginosa can cause pneumonia, septicemia, urinary tract, and surgery site infections mainly in immunocompromised people, although it can cause infections in many different patient profiles. Cystic fibrosis patients are particularly vulnerable. In vitro and in vivo studies of phage therapy against P. aeruginosa include both bacteriophages alone and combined with antibiotics. However, the former is the most promising strategy utilized in clinical infections. This review summarizes the recent studies of phage-antibiotic combinations, highlighting the synergistic effects of in vitro and in vivo experiments and successful treatments in patients.<\/jats:p>","DOI":"10.3390\/antibiotics12071089","type":"journal-article","created":{"date-parts":[[2023,6,23]],"date-time":"2023-06-23T01:54:56Z","timestamp":1687485296000},"page":"1089","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":26,"title":["Bacteriophage\u2013Antibiotic Combination Therapy against Pseudomonas aeruginosa"],"prefix":"10.3390","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7544-0604","authenticated-orcid":false,"given":"Guillermo","family":"Santamar\u00eda-Corral","sequence":"first","affiliation":[{"name":"Department of Clinical Microbiology, IIS-Fundaci\u00f3n Jim\u00e9nez D\u00edaz, Av. Reyes Cat\u00f3licos 2, 28040 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0031-0976","authenticated-orcid":false,"given":"Abrar","family":"Senhaji-Kacha","sequence":"additional","affiliation":[{"name":"Department of Clinical Microbiology, IIS-Fundaci\u00f3n Jim\u00e9nez D\u00edaz, Av. Reyes Cat\u00f3licos 2, 28040 Madrid, Spain"},{"name":"CIBERINFEC\u2014Infectious Diseases CIBER, 28029 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Broncano-Lavado","sequence":"additional","affiliation":[{"name":"Department of Clinical Microbiology, IIS-Fundaci\u00f3n Jim\u00e9nez D\u00edaz, Av. Reyes Cat\u00f3licos 2, 28040 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8971-3167","authenticated-orcid":false,"given":"Jaime","family":"Esteban","sequence":"additional","affiliation":[{"name":"Department of Clinical Microbiology, IIS-Fundaci\u00f3n Jim\u00e9nez D\u00edaz, Av. Reyes Cat\u00f3licos 2, 28040 Madrid, Spain"},{"name":"CIBERINFEC\u2014Infectious Diseases CIBER, 28029 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meritxell","family":"Garc\u00eda-Quintanilla","sequence":"additional","affiliation":[{"name":"Department of Clinical Microbiology, IIS-Fundaci\u00f3n Jim\u00e9nez D\u00edaz, Av. Reyes Cat\u00f3licos 2, 28040 Madrid, Spain"},{"name":"CIBERINFEC\u2014Infectious Diseases CIBER, 28029 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,6,22]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1016\/j.cmet.2020.04.017","article-title":"Pseudomonas aeruginosa Utilizes Host-Derived Itaconate to Redirect Its Metabolism to Promote Biofilm Formation","volume":"31","author":"Riquelme","year":"2020","journal-title":"Cell Metab."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.jinf.2016.11.008","article-title":"Intensive care unit-acquired pneumonia due to Pseudomonas aeruginosa with and without multidrug resistance","volume":"74","author":"Ferrer","year":"2017","journal-title":"J. Infect."},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Jurado-Mart\u00edn, I., Sainz-Mej\u00edas, M., and McClean, S. (2021). Pseudomonas aeruginosa: An Audacious Pathogen with an Adaptable Arsenal of Virulence Factors. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22063128"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1007\/s40265-021-01635-6","article-title":"The Epidemiology and Pathogenesis and Treatment of Pseudomonas aeruginosa Infections: An Update","volume":"81","author":"Reynolds","year":"2021","journal-title":"Drugs"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1097\/QCO.0b013e32833f0d3e","article-title":"Multiresistant Gram-negative infections: A global perspective","volume":"23","author":"Ho","year":"2010","journal-title":"Curr. Opin. Infect. Dis."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1111\/j.1476-5381.2011.01250.x","article-title":"Novel classes of antibiotics or more of the same?","volume":"163","author":"Coates","year":"2011","journal-title":"Br. J. Pharmacol."},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Horcajada, J.P., Montero, M., Oliver, A., Sorl\u00ed, L., Luque, S., G\u00f3mez-Zorrilla, S., Benito, N., and Grau, S. (2019). Epidemiology and treatment of multidrug-resistant and extensively drug-resistant Pseudomonas aeruginosa infections. Clin. Microbiol. Rev., 32.","DOI":"10.1128\/CMR.00031-19"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1016\/j.eimc.2010.05.001","article-title":"Interpretive reading of the non-fermenting gram-negative bacilli antibiogram","volume":"28","author":"Vila","year":"2010","journal-title":"Enferm. Infecc. Microbiol. Clin."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1128\/CMR.00040-09","article-title":"Antibacterial-resistant Pseudomonas aeruginosa: Clinical impact and complex regulation of chromosomally encoded resistance mechanisms","volume":"22","author":"Lister","year":"2009","journal-title":"Clin. Microbiol. Rev."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1111\/j.1469-0691.2009.03116.x","article-title":"Acquired carbapenemases in Gram-negative bacterial pathogens: Detection and surveillance issues","volume":"16","author":"Miriagou","year":"2010","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1177\/1753425909106436","article-title":"Review: Lipopolysaccharide biosynthesis in Pseudomonas aeruginosa","volume":"15","author":"King","year":"2009","journal-title":"Innate Immun."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1093\/femsre\/fux020","article-title":"Structure, function and regulation of Pseudomonas aeruginosa porins","volume":"41","author":"Chevalier","year":"2017","journal-title":"FEMS Microbiol. Rev."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.4014\/jmb.1611.11056","article-title":"Pseudomonas aeruginosa Biofilm, a Programmed Bacterial Life for Fitness","volume":"27","author":"Lee","year":"2017","journal-title":"J. Microbiol. Biotechnol."},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Cross, A.R., Raghuram, V., Wang, Z., Dey, D., and Goldberg, J.B. (2020). Overproduction of the AlgT Sigma Factor Is Lethal to Mucoid Pseudomonas aeruginosa. J. Bacteriol., 202.","DOI":"10.1128\/JB.00445-20"},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Hall, S., McDermott, C., Anoopkumar-Dukie, S., McFarland, A.J., Forbes, A., Perkins, A.V., Davey, A.K., Chess-Williams, R., Kiefel, M.J., and Arora, D. (2016). Cellular Effects of Pyocyanin, a Secreted Virulence Factor of Pseudomonas aeruginosa. Toxins, 8.","DOI":"10.3390\/toxins8080236"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"109172","DOI":"10.1016\/j.celrep.2021.109172","article-title":"Temperate phage-antibiotic synergy eradicates bacteria through depletion of lysogens","volume":"35","author":"Fatima","year":"2021","journal-title":"Cell Rep."},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Liu, C.G., Green, S.I., Min, L., Clark, J.R., Salazar, K.C., Terwilliger, A.L., Kaplan, H.B., Trautner, B.W., Ramig, R.F., and Maresso, A.W. (2020). Phage-antibiotic synergy is driven by a unique combination of antibacterial mechanism of action and stoichiometry. MBio, 11.","DOI":"10.1101\/2020.02.27.967034"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1146\/annurev-med-080219-122208","article-title":"Phage Therapy for Antibiotic-Resistant Bacterial Infections","volume":"73","author":"Hatfull","year":"2022","journal-title":"Annu. Rev. Med."},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Nikolic, I., Vukovic, D., Gavric, D., Cvetanovic, J., Aleksic Sabo, V., Gostimirovic, S., Narancic, J., and Knezevic, P. (2022). An Optimized Checkerboard Method for Phage-Antibiotic Synergy Detection. Viruses, 14.","DOI":"10.3390\/v14071542"},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Engeman, E., Freyberger, H.R., Corey, B.W., Ward, A.M., He, Y., Nikolich, M.P., Filippov, A.A., Tyner, S.D., and Jacobs, A.C. (2021). Synergistic Killing and Re-Sensitization of Pseudomonas aeruginosa to Antibiotics by Phage-Antibiotic Combination Treatment. Pharmaceuticals, 14.","DOI":"10.3390\/ph14030184"},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Xuan, G., Lin, H., Kong, J., and Wang, J. (2022). Phage Resistance Evolution Induces the Sensitivity of Specific Antibiotics in Pseudomonas aeruginosa PAO1. Microbiol. Spectr., 10.","DOI":"10.1128\/spectrum.01356-22"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"5725","DOI":"10.1038\/s41467-022-33294-w","article-title":"Bacteriophage-antibiotic combination therapy against extensively drug-resistant Pseudomonas aeruginosa infection to allow liver transplantation in a toddler","volume":"13","author":"Chatzis","year":"2022","journal-title":"Nat. Commun."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"851310","DOI":"10.3389\/fmed.2022.851310","article-title":"Use of Phage Cocktail BFC 1.10 in Combination With Ceftazidime-Avibactam in the Treatment of Multidrug-Resistant Pseudomonas aeruginosa Femur Osteomyelitis\u2014A Case Report","volume":"9","author":"Racenis","year":"2022","journal-title":"Front. Med."},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Damir, G., and Knezevic, P. (2022). Filamentous Pseudomonas Phage Pf4 in the Context of Therapy-Inducibility, Infectivity, Lysogenic Conversion, and Potential Application. Viruses, 14.","DOI":"10.3390\/v14061261"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1636","DOI":"10.1111\/jam.15647","article-title":"Bacteriophage-antibiotic combination therapy for multidrug-resistant Pseudomonas aeruginosa: In vitro synergy testing","volume":"133","author":"Holger","year":"2022","journal-title":"J. Appl. Microbiol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1004733","DOI":"10.3389\/fmicb.2022.1004733","article-title":"Phage-resistant Pseudomonas aeruginosa against a novel lytic phage JJ01 exhibits hypersensitivity to colistin and reduces biofilm production","volume":"13","author":"Wannasrichan","year":"2022","journal-title":"Front. Microbiol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"783722","DOI":"10.3389\/fmicb.2021.783722","article-title":"Survival Comes at a Cost: A Coevolution of Phage and Its Host Leads to Phage Resistance and Antibiotic Sensitivity of Pseudomonas aeruginosa Multidrug Resistant Strains","volume":"12","author":"Valappil","year":"2021","journal-title":"Front. Microbiol."},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Fiscarelli, E.V., Rossitto, M., Rosati, P., Essa, N., Crocetta, V., Giulio, A.D., Lupetti, V., Bonaventura, G.D., and Pompilio, A. (2021). In Vitro Newly Isolated Environmental Phage Activity against Biofilms Preformed by Pseudomonas aeruginosa from Patients with Cystic Fibrosis. Microorganisms, 9.","DOI":"10.3390\/microorganisms9030478"},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Aghaee, B.L., Mirzaei, M.K., Alikhani, M.Y., Mojtahedi, A., and Maurice, C.F. (2021). Improving the Inhibitory Effect of Phages against Pseudomonas aeruginosa Isolated from a Burn Patient Using a Combination of Phages and Antibiotics. Viruses, 13.","DOI":"10.3390\/v13020334"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1093\/emph\/eoaa026","article-title":"Phage steering of antibiotic-resistance evolution in the bacterial pathogen, Pseudomonas aeruginosa","volume":"2020","author":"Gurney","year":"2020","journal-title":"Evol. Med. Public Health"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1007\/s00705-018-3811-0","article-title":"Piperacillin and ceftazidime produce the strongest synergistic phage\u2013antibiotic effect in Pseudomonas aeruginosa","volume":"163","author":"Uchiyama","year":"2018","journal-title":"Arch. Virol."},{"key":"ref_32","unstructured":"CLSI (2018). Methods dilution Antimicrobial Susceptibility Tests Bact That Grow Aerobically, Clinical and Laboratory Standards Institute. [11th ed.]. CLSI standard M07."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1007\/s11538-022-01006-6","article-title":"Phage-antibiotic synergy inhibited by temperate and chronic virus competition","volume":"84","author":"Landa","year":"2022","journal-title":"Bull. Math. Biol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1128\/br.17.4.269-337.1953","article-title":"Lysogeny","volume":"17","author":"Lwoff","year":"1953","journal-title":"Bacteriol. Rev."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.femsre.2003.08.001","article-title":"Ecology of prokaryotic viruses","volume":"28","author":"Weinbauer","year":"2004","journal-title":"FEMS Microbiol. Rev."},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Rodriguez-Gonzalez, R.A., Leung, Y., Chan, B.K., Turner, P.E., and Weitz, J.S. (2020). Quantitative Models of Phage-Antibiotic Combination Therapy. mSystems, 5.","DOI":"10.1128\/mSystems.00756-19"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1111\/jam.14241","article-title":"Antibiofilm potential of purified environmental bacteriophage preparations against early stage Pseudomonas aeruginosa biofilms","volume":"126","author":"Issa","year":"2019","journal-title":"J. Appl. Microbiol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"ftz011","DOI":"10.1093\/femspd\/ftz011","article-title":"P. aeruginosa flow-cell biofilms are enhanced by repeated phage treatments but can be eradicated by phage-ciprofloxacin combination-monitoring the phage-P. aeruginosa biofilms interactions","volume":"77","author":"Henriksen","year":"2019","journal-title":"Pathog. Dis."},{"key":"ref_39","doi-asserted-by":"crossref","unstructured":"Manohar, P., Loh, B., Nachimuthu, R., Leptihn, S., and Nachimuthu Assistant Professor, R. (2022). Phage-antibiotic combinations to control Pseudomonas aeruginosa-Candida two-species biofilms. bioRxiv.","DOI":"10.1101\/2022.08.18.504394"},{"key":"ref_40","doi-asserted-by":"crossref","unstructured":"Danis-Wlodarczyk, K.M., Cai, A., Chen, A., Gittrich, M.R., Sullivan, M.B., Wozniak, D.J., and Abedon, S.T. (2021). Friends or Foes? Rapid Determination of Dissimilar Colistin and Ciprofloxacin Antagonism of Pseudomonas aeruginosa Phages. Pharmaceuticals, 14.","DOI":"10.3390\/ph14111162"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/j.ejpb.2019.08.004","article-title":"Inhalable combination powder formulations of phage and ciprofloxacin for P. aeruginosa respiratory infections","volume":"142","author":"Lin","year":"2019","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.ijpharm.2018.09.024","article-title":"Synergy of nebulized phage PEV20 and ciprofloxacin combination against Pseudomonas aeruginosa","volume":"15","author":"Lin","year":"2018","journal-title":"Int. J. Pharm."},{"key":"ref_43","first-page":"49","article-title":"Bacteriophage PEV20 and ciprofloxacin combination treatment enhances removal of P. aeruginosa biofilm isolated from cystic fibrosis and wound patients. HHS Public Access","volume":"21","author":"Das","year":"2020","journal-title":"AAPS J."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1947","DOI":"10.3389\/fmicb.2020.01947","article-title":"van Combined Bacteriophage and Antibiotic Treatment Prevents Pseudomonas aeruginosa Infection of Wild Type and cftr- Epithelial Cells","volume":"11","author":"Luscher","year":"2020","journal-title":"Front. Microbiol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"e0287422","DOI":"10.1128\/spectrum.02874-22","article-title":"The Selection of Antibiotic- and Bacteriophage-Resistant Pseudomonas aeruginosa Is Prevented by Their Combination","volume":"10","author":"Ferran","year":"2022","journal-title":"Microbiol. Spectr."},{"key":"ref_46","doi-asserted-by":"crossref","unstructured":"Akturk, E., Oliveira, H., Santos, S.B., Costa, S., Kuyumcu, S., Melo, D.R., and Azeredo, J. (2019). Synergistic Action of Phage and Antibiotics: Parameters to Enhance the Killing E ffi cacy Against Mono and Dual-Species Biofilms. Antibiotics, 8.","DOI":"10.3390\/antibiotics8030103"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"695","DOI":"10.3389\/fmicb.2020.00695","article-title":"Using Bacteriophages as a Trojan Horse to the Killing of Dual-Species Biofilm Formed by Pseudomonas aeruginosa and Methicillin Resistant Staphylococcus aureus","volume":"11","author":"Tkhilaishvili","year":"2020","journal-title":"Front. Microbiol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.ejpb.2020.11.019","article-title":"Synergistic activity of phage PEV20-ciprofloxacin combination powder formulation\u2014A proof-of-principle study in a P. aeruginosa lung infection model","volume":"158","author":"Lin","year":"2021","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"ref_49","doi-asserted-by":"crossref","unstructured":"Duplessis, C., Warawa, J.M., Lawrenz, M.B., Henry, M., and Biswas, B. (2021). Successful intratracheal treatment of phage and antibiotic combination therapy of a multi-drug resistant Pseudomonas aeruginosa murine model. Antibiotics, 10.","DOI":"10.3390\/antibiotics10080946"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1038\/s41598-018-37636-x","article-title":"Phage therapy against Pseudomonas aeruginosa infections in a cystic fibrosis zebrafish model","volume":"9","author":"Cafora","year":"2019","journal-title":"Sci. Rep."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"569159","DOI":"10.3389\/fmed.2021.569159","article-title":"Case Report: Arthroscopic \u201cDebridement Antibiotics and Implant Retention\u201d With Local Injection of Personalized Phage Therapy to Salvage a Relapsing Pseudomonas aeruginosa Prosthetic Knee Infection","volume":"8","author":"Ferry","year":"2021","journal-title":"Front. Med."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"4239","DOI":"10.1038\/s41467-022-31837-9","article-title":"Personalized bacteriophage therapy to treat pandrug-resistant spinal Pseudomonas aeruginosa infection","volume":"13","author":"Ferry","year":"2022","journal-title":"Nat. Commun."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"2901","DOI":"10.1093\/jac\/dky263","article-title":"Innovations for the treatment of a complex bone and joint infection due to XDR Pseudomonas aeruginosa including local application of a selected cocktail of bacteriophages","volume":"73","author":"Ferry","year":"2018","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1007\/s15010-019-01319-0","article-title":"Successful adjunctive use of bacteriophage therapy for treatment of multidrug-resistant Pseudomonas aeruginosa infection in a cystic fibrosis patient","volume":"47","author":"Law","year":"2019","journal-title":"Infection"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"2631","DOI":"10.1111\/ajt.15503","article-title":"Early clinical experience of bacteriophage therapy in 3 lung transplant recipients","volume":"19","author":"Aslam","year":"2019","journal-title":"Am. J. Transplant."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"158","DOI":"10.5582\/bst.2022.01147","article-title":"Bacteriophage therapy for empyema caused by carbapenem-resistant Pseudomonas aeruginosa","volume":"16","author":"Chen","year":"2022","journal-title":"Biosci. Trends"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1093\/emph\/eoy005","article-title":"Phage treatment of an aortic graft infected with Pseudomonas aeruginosa","volume":"2018","author":"Chan","year":"2018","journal-title":"Evol. Med. Public Health"},{"key":"ref_58","doi-asserted-by":"crossref","unstructured":"Rubalskii, E., Ruemke, S., Salmoukas, C., Boyle, E.C., Warnecke, G., Tudorache, I., Shrestha, M., Schmitto, J.D., Martens, A., and Rojas, S.V. (2020). Bacteriophage Therapy for Critical Infections Related to Cardiothoracic Surgery. Antibiotics, 9.","DOI":"10.3390\/antibiotics9050232"},{"key":"ref_59","doi-asserted-by":"crossref","unstructured":"Tkhilaishvili, T., Winkler, T., M\u00fcller, M., Perka, C., and Trampuz, A. (2019). Bacteriophages as Adjuvant to Antibiotics for the Treatment of Periprosthetic Joint Infection Caused by Multidrug-Resistant Pseudomonas aeruginosa. Antimicrob. Agents Chemother., 64.","DOI":"10.1128\/AAC.00924-19"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"dlac046","DOI":"10.1093\/jacamr\/dlac046","article-title":"Combination of phage therapy and cefiderocol to successfully treat Pseudomonas aeruginosa cranial osteomyelitis","volume":"4","author":"Simner","year":"2023","journal-title":"JAC Antimicrob. Resist."}],"container-title":["Antibiotics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2079-6382\/12\/7\/1089\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T19:58:41Z","timestamp":1760126321000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2079-6382\/12\/7\/1089"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,22]]},"references-count":60,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2023,7]]}},"alternative-id":["antibiotics12071089"],"URL":"https:\/\/doi.org\/10.3390\/antibiotics12071089","relation":{},"ISSN":["2079-6382"],"issn-type":[{"value":"2079-6382","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,22]]}}}